Core Insights - The newly released commercial insurance innovative drug directory includes 19 drugs, with 6 specifically for rare diseases, addressing conditions such as neuroblastoma and Gaucher disease [1][3] - The directory aims to provide a reference for multi-tiered medical insurance systems, but attracting more commercial insurance participation remains a challenge [1][6] Summary by Sections Rare Disease Drug Inclusion - The innovative drug for short bowel syndrome, injection of teduglutide, is set to be the first GLP-2 analog approved in China, filling a long-standing gap in treatment options [3][4] - Gaucher disease, affecting approximately 3,000 patients in China, now has a locally developed enzyme replacement therapy, injection of velaglucerase alfa, included in the directory [5] Challenges in Commercial Insurance - The increasing pressure on basic medical insurance funds makes it unrealistic to rely solely on them for rare disease drug coverage, highlighting the need for commercial insurance products like Huiminbao [6][8] - Huiminbao has made strides in covering certain rare disease drugs, but the number of drugs and policies available for rare diseases still needs improvement [8] Future Directions - Experts suggest that a multi-tiered approach involving basic insurance, commercial insurance, and charitable support is essential for effective rare disease drug coverage [9][10] - The focus should shift from post-reimbursement to comprehensive service and long-term health management for rare disease patients [10]

Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog, along with the first version of the Commercial Health Insurance Innovative Drug Catalog, will be officially implemented on January 1, 2026 [1][2] Group 1: National Medical Insurance Drug Catalog - The 2025 update adds 114 new drugs, including 50 innovative drugs, while removing 29 drugs that are either not clinically available or can be replaced by better alternatives [1] - The total number of drugs in the catalog increases to 3,253, comprising 1,857 Western medicines and 1,396 traditional Chinese medicines [1] - New drugs included address significant medical needs, such as treatments for triple-negative breast cancer, pancreatic cancer, lung cancer, rare diseases, and chronic conditions like diabetes and autoimmune diseases [1] Group 2: Commercial Health Insurance Innovative Drug Catalog - The catalog includes 19 drugs from 18 innovative pharmaceutical companies, featuring advanced therapies such as CAR-T, TCE therapies, and bispecific antibodies [2] - The catalog emphasizes three key characteristics: support for innovation, focus on critical areas like Alzheimer's and pediatric rare diseases, and the distinction between basic medical insurance and commercial insurance [2] Group 3: Future Directions - The National Medical Insurance Administration aims to clarify the boundaries of basic medical insurance and promote the complementary development of commercial health insurance, establishing a multi-tiered medical security system [3] - Future policies will be refined to enhance management and ensure the effective implementation of the drug catalogs, ultimately improving the clinical medication needs of insured individuals [3]

Report Summary 1. Report Industry Investment Rating - Not provided in the report 2. Core Viewpoints - In December 2025, the global financial market will witness two major policy events: the Fed's December interest rate meeting and China's Central Economic Work Conference. The Fed's decision will impact global capital flows and risk appetite, while the Central Economic Work Conference will clarify China's economic policy framework and industrial development direction for 2026. Before the official implementation of the policies of the two meetings, funds may be more cautious, and the stock market is expected to remain volatile. After the meeting content is clear, the positive policy signals and the Fed's interest rate cuts will resonate, and the market risk preference is expected to rise again [2] 3. Summary of Each Section 3.1 Stock Index Futures Market - **IF Contracts**: The previous day's closing prices of IF contracts (including the current month, next month, next quarter, and the quarter after next) increased, with price increases of 46.00, 46.40, 45.20, and 46.20 respectively, and price increases of 1.02%, 1.03%, 1.01%, and 1.04%. The trading volumes were 84,754.00, 5,005.00, 29,046.00, and 6,014.00 respectively. The positions increased by 6,821.00, 2,041.00, 5,658.00, and 707.00 respectively [1] - **IH Contracts**: The previous day's closing prices of IH contracts increased, with price increases of 32.00, 32.40, 32.20, and 32.80 respectively, and price increases of 1.08%, 1.10%, 1.09%, and 1.12%. The trading volumes were 38,569.00, 2,721.00, 12,268.00, and 3,123.00 respectively. The positions increased by 6,493.00, 1,333.00, 2,695.00, and 1,013.00 respectively [1] - **IC Contracts**: The previous day's closing prices of IC contracts increased, with price increases of 107.60, 102.60, 103.80, and 105.40 respectively, and price increases of 1.54%, 1.48%, 1.53%, and 1.60%. The trading volumes were 83,349.00, 5,876.00, 33,919.00, and 8,827.00 respectively. The positions increased by 7,712.00, 1,722.00, 6,121.00, and 634.00 respectively [1] - **IM Contracts**: The previous day's closing prices of IM contracts increased, with price increases of 115.80, 112.80, 109.60, and 107.00 respectively, and price increases of 1.61%, 1.58%, 1.57%, and 1.59%. The trading volumes were 146,937.00, 10,614.00, 47,651.00, and 15,250.00 respectively. The positions increased by 8,115.00, 3,280.00, 6,975.00, and 1,387.00 respectively [1] - **Inter - month Spreads**: The current values of the inter - month spreads of IF, IH, IC, and IM contracts were -17.40, -6.80, -59.40, and -77.20 respectively, compared with the previous values of -18.40, -8.40, -57.00, and -76.20 [1] 3.2 Stock Index Spot Market - **Major Indexes**: The previous day's closing prices of the CSI 300, SSE 50, CSI 500, and CSI 1000 indexes increased, with price increases of 37.97, 27.67, 85.03, and 93.83 respectively, and price increases of 0.84%, 0.93%, 1.21%, and 1.29%. The trading volumes (in billions of lots) were 196.80, 44.60, 168.74, and 215.73 respectively, and the total trading amounts (in billions of RMB) were 4,121.47, 1,104.47, 2,751.08, and 3,528.06 respectively [1] - **Industry Indexes**: Among the CSI 300 industry indexes, the raw materials, industry, optional consumption, major consumption, medical and health, real estate and finance, information technology, and telecommunications services sectors increased, with price increases of 2.07%, 1.16%, 0.44%, 0.30%, 0.65%, 1.33%, 0.14%, and 0.43% respectively. The energy and public utilities sectors decreased, with price decreases of 0.57% and 0.24% respectively [1] 3.3 Futures - Spot Basis - The previous day's values of the futures - spot basis of IF, IH, IC, and IM contracts (compared with their corresponding spot indexes) were higher than the values of the day before the previous day, indicating a narrowing of the basis [1] 3.4 Other Domestic and Overseas Indexes - **Domestic Indexes**: The previous day's closing prices of the Shanghai Composite Index, Shenzhen Component Index, Small - and Medium - Cap Board Index, and ChiNext Index increased, with price increases of 0.70%, 1.08%, 0.68%, and 1.36% respectively [1] - **Overseas Indexes**: The previous day's closing prices of the Hang Seng Index, Nikkei 225, S&P 500, and DAX Index increased, with price increases of 0.58%, 2.33%, 0.19%, and 0.61% respectively [1] 3.5 Macroeconomic Information - The Ministry of Industry and Information Technology will focus on promoting the stable growth of the industrial economy, comprehensively deepening reforms, and ensuring the security of key industrial chains and supply chains [2] - As of the end of November 2025, China's foreign exchange reserves reached 3.3464 trillion US dollars, an increase of 0.09% compared with the end of October, and the central bank's gold reserves increased for the 13th consecutive month [2] - From January to November, the number of new disclosure of shareholding increase plans by Shanghai - listed companies was 210 times, with the upper limit of the planned shareholding increase amount reaching 64.984 billion RMB, a year - on - year increase of 25.43% [2] - In 2025, the issuance of Fund of Funds (FOF) boomed. As of December 7, 74 new public - offering FOFs were established, with a total issuance scale of 77.606 billion RMB, reaching a new high in the past four years [2] 3.6 Industry Information - Multiple rare - disease drugs were included in the 2025 medical insurance catalog and the commercial insurance innovative drug catalog, and five CAR - T drugs were included in the commercial insurance innovative drug catalog [2] - In October, the global semiconductor sales increased by 33% year - on - year to 71.3 billion US dollars, and the DRAM sales increased by 90% year - on - year, mainly driven by the demand for artificial intelligence [2] - The 2025 Cultured Diamond Industry Conference was held in Zhengzhou. Henan's annual output of cultured diamonds is nearly 25 million carats, but there is a lack of high - end differentiated brands. It is expected that by 2030, there will be more than 10 well - known Chinese cultured diamond brands and 1 - 2 international brands [2]

Core Viewpoint - The article highlights a significant rise in the stock prices of several innovative pharmaceutical companies following the announcement of the 2025 National Medical Insurance drug list, which includes a substantial number of new innovative drugs [1] Group 1: Stock Performance - WuXi AppTec (02126) saw an increase of 8.77%, trading at HKD 3.35 [1] - Kintor Pharmaceutical (02171) rose by 3.8%, reaching HKD 18.87 [1] - Beihai Kangcheng (01228) increased by 3.38%, priced at HKD 2.45 [1] - Junshi Biosciences (01877) gained 2.29%, with a share price of HKD 24.1 [1] Group 2: Drug List Adjustments - The 2025 National Medical Insurance drug list is the 8th adjustment since the establishment of the National Healthcare Security Administration [1] - A total of 114 new drugs were added to the list, including 50 Class 1 innovative drugs [1] Group 3: Notable Drug Inclusions - Fosun Pharma's (600196) Luwomei Tablets and Beihai Kangcheng's injectable Vilazodone Beta were included in the commercial insurance innovative drug list [1] - The highly anticipated CAR-T cell therapies from various companies, including Fosun Kairui's Acalabrutinib Injection and WuXi AppTec's Regorafenib Injection, were also included in the first batch of commercial insurance innovative drug list [1]

Group 1 - The core viewpoint of the article highlights a significant rise in certain innovative drug concept stocks, driven by the recent adjustment of the national medical insurance drug list in China, which includes 114 new drugs, 50 of which are classified as innovative drugs [1] - WuXi AppTec's stock (02126) increased by 8.77% to HKD 3.35, Kintor Pharmaceutical's stock (02171) rose by 3.8% to HKD 18.87, Beihai Kangcheng's stock (01228) went up by 3.38% to HKD 2.45, and Junshi Biosciences (01877) saw a 2.29% increase to HKD 24.1 [1] - Notably, Fosun Pharma's drug, Luwomei Tablets, has been included in the 2025 medical insurance directory, while Beihai Kangcheng's injectable Viraquinase β has entered the commercial insurance innovative drug directory [1] Group 2 - The article emphasizes the inclusion of several CAR-T cell therapies in the first batch of commercial insurance innovative drug directory, including Fosun Kairui's Acalabrutinib injection, WuXi AppTec's Regorafenib injection, and others from various biotech companies [1] - The adjustment of the medical insurance drug list marks the 8th update since the establishment of the National Medical Insurance Bureau, indicating ongoing efforts to enhance access to innovative treatments [1]

国家医保局等部门印发《国家基本医疗保险、生育保险和工伤保险药品目录》以及《商业健康保险创新 药品目录》，自2026年1月1日起正式执行。 国家医保局成立以来医保药品目录已调整8次，本次医保药品目录调整新增114种药品，其中50种为1类 创新药。首版商保创新药目录共纳入19种药品，既有CAR-T等肿瘤治疗药品，也有社会关注度较高的阿 尔茨海默病治疗药品。 恒生医药ETF（159892）聚焦创新药产业，在港交所18A制度优势下覆盖众多创新标的（百济神州、信 达生物、康方生物等），有望受益于医保目录的更新和美联储降息。 （文章来源：每日经济新闻） 具体来看，复星医药的芦沃美替尼片进入2025年医保目录，北海康成的注射用维拉苷酶β进入商保创新 药目录。同时，5款CAR-T药进入商保创新药目录，分别是复星凯瑞的阿基仑赛注射液、药明巨诺的瑞 基奥仑赛注射液、合源生物的纳基奥仑赛注射液、驯鹿生物的伊基奥仑赛注射液、科济药业的泽沃基奥 仑赛注射液。 从药企角度来看，纳入医保+商保的创新药大多处于放量初期，随着政策红利释放，纳入医保、商保目 录的创新药有望快速放量。商保的逐步推广也有望增加创新药费用的支付来源，促进创新药在支付 ...

Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have issued a new drug catalog for basic medical insurance, maternity insurance, and work injury insurance, which will take effect on January 1, 2026. This marks the 8th adjustment of the medical insurance drug catalog since the establishment of the National Healthcare Security Administration [1] - The recent adjustment adds 114 new drugs, including 50 first-class innovative drugs. Notably, several rare disease medications have been included in the 2025 medical insurance catalog and the commercial health insurance innovative drug catalog [1] - Specific drugs such as Fosun Pharma's Luvofemin and Beihai Kangcheng's Vilazodone have been included in the 2025 medical insurance catalog and the commercial health insurance innovative drug catalog, respectively. Additionally, five CAR-T therapies have been added to the commercial health insurance innovative drug catalog [1] Group 2 - John Yang, the Asia-Pacific healthcare research director at Citibank, stated that biotechnology, particularly innovative drugs, will be a top priority for China in the coming years. He emphasized the need for China to upgrade production lines and capabilities, as well as expand clinical management capabilities to develop the entire ecosystem [1] - Morgan Stanley's healthcare research head in China, Yang Huang, echoed similar sentiments, noting that biomanufacturing has been identified by the government as a key economic growth driver during the 14th Five-Year Plan period [1] Group 3 - The head of the National Healthcare Security Administration, Zhang Ke, indicated plans to accelerate the construction of a healthcare imaging cloud based on medical insurance data, aiming for nationwide interoperability and recognition of medical insurance imaging by 2027 [4]

Core Insights - The 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalog and the first Commercial Health Insurance Innovative Drug Catalog were officially released on December 7, highlighting significant advancements in drug accessibility and innovation support [1][6]. Summary by Sections Basic Medical Insurance Drug Catalog - A total of 114 new drugs were added, with 50 being first-class innovative drugs, achieving an overall success rate of 88%, an increase from 76% in 2024 [3][5]. - The total number of drugs in the National Medical Insurance Drug Catalog has increased to 3,253, including 1,857 Western medicines and 1,396 traditional Chinese medicines, with enhanced coverage for critical areas such as cancer, chronic diseases, mental illnesses, rare diseases, and pediatric medications [3][5]. - The new drug catalog will be implemented starting January 1, 2026, with a six-month transition period for drugs that were not successfully renewed [3][4]. Commercial Health Insurance Innovative Drug Catalog - The Commercial Health Insurance Innovative Drug Catalog includes 19 drugs from 18 innovative pharmaceutical companies, focusing on high clinical value and innovation, particularly in cancer, rare diseases, and chronic conditions [7][9]. - The catalog emphasizes three main characteristics: support for innovation, focus on key therapeutic areas, and a clear distinction between basic medical insurance and commercial insurance coverage [7][9]. - Notable inclusions are five CAR-T products and new treatments for Alzheimer's disease and Gaucher disease, reflecting a trend towards covering high-cost, innovative therapies through commercial insurance [8][9]. Innovation and Market Impact - The inclusion of a significant number of first-class innovative drugs in the basic medical insurance catalog demonstrates the government's commitment to enhancing drug accessibility and encouraging pharmaceutical innovation [6][9]. - The successful negotiation rates and the focus on innovative drugs in both catalogs are expected to stimulate further investment in drug research and development by pharmaceutical companies [6][9].

Core Insights - The seminar held in Shanghai on December 7 focused on accelerating the construction of the "Five Centers" during the 14th Five-Year Plan period, addressing new opportunities and challenges arising from significant changes in domestic and international development [1] Group 1: Innovation in Biopharmaceuticals - Shanghai has initiated a pilot project for segmented production of biopharmaceuticals, successfully launching the first domestic project for innovative drug production, attracting an investment of 3.14 billion yuan from Roche and other companies [2] - The segmented production model has been incorporated into local regulations, enhancing the efficiency of biopharmaceutical resource allocation [2] Group 2: Telecommunications and Digital Services - Shanghai has become the first in the country to pilot the expansion of value-added telecommunications services, allowing foreign companies to operate independently in specific zones, with nine foreign enterprises currently participating [2] - This initiative aims to deepen foreign investment in digital services, including cloud computing and data processing [2] Group 3: Artificial Intelligence Development - The establishment of a large-scale humanoid robot training ground aims to transition embodied intelligence from research to practical applications, achieving a model transfer success rate of over 95% [3] - This initiative supports various sectors, including smart manufacturing and public services, enhancing robots' capabilities in complex environments [3] Group 4: International Financial Center - The Shanghai International Reinsurance Registration and Trading Center has achieved a digital and standardized transformation, with 131 institutions registered and a trading premium of 5.3 billion yuan recorded in the first ten months of 2025 [4] - A pilot reform for offshore trade finance services has been launched, significantly improving cross-border settlement efficiency for offshore trade enterprises [4] Group 5: Technology Innovation and Support - The introduction of a growth tier in the Sci-Tech Innovation Board aims to support technology companies with significant breakthroughs but currently unprofitable, with a total market value of nearly 1.3 trillion yuan for 35 listed companies [5] - The Shanghai government has implemented a "no application required" policy for technology innovation vouchers, benefiting over 30,000 small and medium-sized tech enterprises and increasing voucher orders by 60% from September to November [12] Group 6: International Trade and Data Economy - Shanghai has piloted measures for the facilitation of imported consumer goods inspections, resulting in 1,040 entries and 2,940 batches benefiting from these measures by September 2025 [7] - The construction of an international data center aims to promote data openness and cooperation, establishing a data economy industrial system that supports cross-border data flow [8] Group 7: Shipping and Maritime Innovation - Shanghai has developed a low-carbon fuel supply system for ships, becoming one of the few ports globally capable of supplying both LNG and green methanol, with 1.45 million cubic meters of LNG supplied to 251 vessels by October 2025 [9] - The implementation of a "one-box" water-to-water transfer model has significantly improved logistics efficiency in the Yangtze River Delta region, with increases in cargo declaration numbers and operational efficiency exceeding 30% [9]

Core Points - The 2025 National Medical Insurance Directory has added 114 new drugs, including 50 innovative drugs, which will significantly enhance patient access to essential medications [1][3][6] - The introduction of the Commercial Health Insurance Innovative Drug Directory marks a pivotal moment for innovative drug accessibility, allowing companies to explore new payment channels beyond traditional insurance [12][13] - The overall number of drugs in the National Medical Insurance Directory has increased to 3,253, with a notable focus on critical areas such as oncology, chronic diseases, and rare diseases [6][11] Group 1: National Medical Insurance Directory - The 2025 National Medical Insurance Directory includes 114 new drugs, with 50 classified as innovative drugs, such as Tislelizumab and domestic ADCs [1][3] - The directory aims to bridge gaps in basic medical insurance coverage for major diseases like triple-negative breast cancer and lung cancer [3][4] - The total number of drugs in the National Medical Insurance Directory has risen to 3,253, enhancing coverage for key disease areas [6] Group 2: Commercial Health Insurance Innovative Drug Directory - The Commercial Health Insurance Innovative Drug Directory includes five CAR-T cell therapies and two Alzheimer's disease drugs, addressing previously limited access due to high costs [1][7] - The directory allows innovative drug companies to seek new payment avenues, enhancing the affordability and accessibility of high-value drugs [12][13] - The introduction of this directory is seen as a significant milestone in improving patient access to innovative therapies [8][9] Group 3: Industry Impact and Future Outlook - The past decade has seen a surge in China's innovative drug development, with the 2025 directory marking a new phase in business development for the industry [11] - The dual-track payment framework of basic insurance and commercial insurance is expected to stimulate the market for innovative drugs [13] - Companies are encouraged to collaborate with insurance providers to enhance patient coverage and awareness of health insurance options [12][13]